Lung Cancer Clinical Trials

Find Lung Cancer Clinical Trials Near You

Collection of Sputum and Sputum Labeling Utilizing Synthetic Meso-Tetra (4-Carboxyphenyl) Porphyrin (TCPP) for Detection of Lung Cancer

Status: Recruiting
Location: See all (3) locations...
Study Type: Observational
SUMMARY

The primary objective of this study is to compare Assay results to diagnoses determined by currently accepted standards for lung cancer detection. This will be accomplished by analysis of sputum samples from three cohorts including healthy Participants, high risk Participants, and cancer patient Participants using the Assay as developed in accordance with findings of bioAffinity protocol BA-001 to confirm assay results. Adjustments will be made as necessary to finalize Assay design for clinical trials and commercialization. The secondary objective of this study is to determine optimum methods for collection of sputum samples. Three sputum collection methods used by high risk Participants will be compared. Individuals at high risk for lung cancer will be assigned to one of three sputum collection cohorts including (1) acapella® airway assist device under medical supervision to obtain a single sputum sample; (2) acapella® airway assist device to obtain a sputum sample over a three-day period, and (3) individuals who under medical supervision will collect a single sputum sample assisted by nebulization of between 0.9% to 10% hypertonic saline. Samples will be compared to determine the optimal collection method for sample analysis by CyPath® Lung.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 21
Healthy Volunteers: t
View:

⁃ Each subject must meet the following criteria to be enrolled in this study:

• Male or female

• 21 years of age or older

• Willing to provide primary care physician contact information to the investigator and agree to have medical information released if indicated

• Meet requirements of one of three cohorts in the study:

⁃ Healthy Cohort: Current non-smoker who has smoked less than 5 pack-years in his or her lifetime, and if smoked, quit more than 15 years ago, and has no known lung disease.

⁃ High Risk Cohort: Individual aged ≥55-74 who is a current smoker with a smoking history of at least 30 pack-years, or current non-smoker who has a smoking history of at least 30 pack-years, and quit smoking within the past 15 years.

⁃ Cancer Cohort: Individual who has been diagnosed by a physician as highly suspect for having lung cancer but has not yet undergone a biopsy nor received therapy, and after providing a sputum sample is confirmed to have lung cancer by biopsy.

Locations
United States
New Jersey
Atlantic Respiratory Institute
RECRUITING
Summit
New Mexico
Radiology Associates of Albuquerque
RECRUITING
Albuquerque
Texas
South Texas Veterans Health Care System (STVHCS)/Audie L. Murphy Memorial Veterans Hospital
RECRUITING
San Antonio
Contact Information
Primary
Maria Zannes, JD
mz@bioaffinitytech.com
505-400-9747
Backup
Xavier Reveles, MS
xr@bioaffinitytech.com
210-698-5334
Time Frame
Start Date: 2018-03-01
Estimated Completion Date: 2025-12
Participants
Target number of participants: 500
Treatments
Healthy Cohort
Healthy Cohort: current non-smoker who has smoked less than 5 pack-years in his or her lifetime, and if smoked, quit more than 15 years ago, and has no known lung disease.
High-risk Cohort
High-risk Cohort: individual aged ≥55-74 who is a current smoker with a smoking history of at least 30 pack-years or current non-smoker who has a smoking history of at least 30 pack-years and quit smoking within the past 15 years.
Cancer Cohort
Cancer Cohort: individual who has been diagnosed by a physician as highly suspect for having lung cancer, but has not yet undergone a biopsy nor received therapy, and after providing a sputum sample is confirmed to have lung cancer by biopsy.
Related Therapeutic Areas
Sponsors
Leads: bioAffinity Technologies Inc.

This content was sourced from clinicaltrials.gov